Search

Author/Creator Patel, Munjal

1. 1159. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-Dose Clinical Trial. (4th December 2021)

Authors:
Bradley, John S; Makieieva, Nataliia; Tøndel, Camilla; Roilides, Emmanuel; Kelly, Matthew S; Patel, Munjal; Vaddady, Pavan; Maniar, Alok; Zhang, Ying; Paschke, Amanda; Butterton, Joan R; Chen, Luke F
Journal:
Open forum infectious diseases
Issue:
Volume 8(2021)Supplement 1
Page Start:
S671
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 1159. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-Dose Clinical Trial. (4th December 2021)

Authors:
Bradley, John S; Makieieva, Nataliia; Tøndel, Camilla; Roilides, Emmanuel; Kelly, Matthew S; Patel, Munjal; Vaddady, Pavan; Maniar, Alok; Zhang, Ying; Paschke, Amanda; Butterton, Joan R; Chen, Luke F
Journal:
Open forum infectious diseases
Issue:
Volume 8(2021)Supplement 1
Page Start:
S671
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). (12th August 2020)

Authors:
Titov, Ivan; Wunderink, Richard G; Roquilly, Antoine; Rodríguez Gonzalez, Daniel; David-Wang, Aileen; Boucher, Helen W; Kaye, Keith S; Losada, Maria C; Du, Jiejun; Tipping, Robert; Rizk, Matthew L; Patel, Munjal; Brown, Michelle L; Young, Katherine; Kartsonis, Nicholas A; Butterton, Joan R; Pasch...
Journal:
Clinical infectious diseases
Issue:
Volume 73:Number 11(2021)
Page Start:
e4539
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance. Issue 2 (4th March 2023)

Authors:
Roberts, Jason A; Nicolau, David P; Martin-Loeches, Ignacio; Deryke, C Andrew; Losada, Maria C; Du, Jiejun; Patel, Munjal; Rizk, Matthew L; Paschke, Amanda; Chen, Luke F
Journal:
JAC-antimicrobial resistance
Issue:
Volume 5:Issue 2(2023)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. In Vitro Pharmacokinetic/Pharmacodynamic Modeling of HIV Latency Reversal by Novel HDAC Inhibitors Using an Automated Platform. (June 2021)

Authors:
Newhard, William; Patel, Munjal; Cassaday, Jason; Ballard, Jeanine; Squadroni, Brian; Wu, Guoxin; Liu, Jian; Yu, Wensheng; Kozlowski, Joe; Zuck, Paul; Howell, Bonnie; Hazuda, Daria; Vargo, Ryan; Barnard, Richard
Journal:
SLAS discovery
Issue:
Volume 26:Number 5(2021)
Page Start:
642
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia. Issue 2 (27th October 2021)

Authors:
Patel, Munjal; Bellanti, Francesco; Daryani, Naveen M.; Noormohamed, Nadia; Hilbert, David W.; Young, Katherine; Kulkarni, Pooja; Copalu, William; Gheyas, Ferdous; Rizk, Matthew L.
Journal:
Clinical and translational science
Issue:
Volume 15:Issue 2(2022)
Page Start:
396
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗